Abstract
Transarterial radioembolization (TARE) with yttrium-90 microspheres has emerged as
an effective therapy for the treatment of both primary and metastatic hepatic lesions.
It has been studied most extensively in hepatocellular carcinoma (HCC) and metastatic
colorectal lesions (mCRC). The clinical success of TARE in HCC and mCRC has led to
further investigation of expanding treatment to other malignancies involving the liver
such as neuroendocrine carcinoma, uveal melanoma, and breast carcinoma, among others.
Furthermore, interest in applications of TARE outside of the liver is emerging and
small initial studies have been performed primarily in animal models to assess the
effects of TARE on other organs such as the brain, stomach, spleen, kidney, and lungs.
This review summarizes existing literature on the use of TARE outside of the liver.
Keywords
radioembolization - renal cell carcinoma - pulmonary metastatic disease - non-small
cell lung cancer - spleen - stomach - glioblastoma
